Design Therapeutics Inc expected to post a loss of 33 cents a share - Earnings Preview

Design Therapeutics

01/08/2025 15:53

Design Therapeutics Inc DSGN.OQ DSGN.O is expected to  show no change in quarterly revenue when it reports  results on August 4 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Design Therapeutics Inc is for a loss of 33 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Design Therapeutics Inc is $5.00, about 22.6% above its last closing price of $3.87

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.29
-0.28
-0.31
Missed
-10.7
Dec. 31 2025
-0.27
-0.24
Beat
10
Sep. 30 2024
-0.22
-0.24
-0.23
Beat
5.5​
Jun. 30 2024
-0.21
-0.23
-0.21
Beat
10
​​Mar. 31 2024
-0.25
-0.26
-0.20
Beat
24.1
Dec. 31 2023
-0.31
-0.21
Beat
32.2​
Sep. 30 2023
-0.38
-0.41
-0.28
Beat
31.5
Jun. 30 2023
-0.39
-0.40
-0.36
Beat
9.4

This summary was machine generated August 1 at 14:53 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)